Fiduciary Trust’s Relay Therapeutics RLAY Stock Holding History

Fiduciary Trust’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Sell	13,971 -14,000	-50%	-$203K	﹤0.01%	787
2026 Q1	$278K	Hold	27,971	–	–	﹤0.01%	762
2025 Q4	$237K	Hold	27,971	–	–	﹤0.01%	794
2025 Q3	$146K	Hold	27,971	–	–	﹤0.01%	834
2025 Q2	$96.8K	Hold	27,971	–	–	﹤0.01%	820
2025 Q1	$73.3K	Hold	27,971	–	–	﹤0.01%	811
2024 Q4	$115K	Hold	27,971	–	–	﹤0.01%	681
2024 Q3	$198K	Hold	27,971	–	–	﹤0.01%	633
2024 Q2	$182K	Hold	27,971	–	–	﹤0.01%	610
2024 Q1	$232K	Hold	27,971	–	–	﹤0.01%	602
2023 Q4	$308K	Hold	27,971	–	–	0.01%	531
2023 Q3	$235K	Hold	27,971	–	–	﹤0.01%	568
2023 Q2	$351K	Hold	27,971	–	–	0.01%	514
2023 Q1	$461K	Hold	27,971	–	–	0.01%	454
2022 Q4	$418K	Hold	27,971	–	–	0.01%	482
2022 Q3	$626K	Hold	27,971	–	–	0.01%	407
2022 Q2	$469K	Hold	27,971	–	–	0.01%	458
2022 Q1	$837K	Hold	27,971	–	–	0.02%	377
2021 Q4	$859K	Hold	27,971	–	–	0.01%	371
2021 Q3	$882K	Hold	27,971	–	–	0.02%	359
2021 Q2	$1.02M	Hold	27,971	–	–	0.02%	329
2021 Q1	$967K	Buy	+27,971	New	+$1.21M	0.02%	335

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fiduciary Trust's RLAY Position: Q2 2026 in Review

Fiduciary Trust reduced its Relay Therapeutics (RLAY) stake by 50% in Q2 2026, selling an estimated $203K and leaving 13,971 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #787.

Fiduciary Trust first reported a position in RLAY in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.02M in Q2 2021. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

Fiduciary Trust held 13,971 shares of Relay Therapeutics worth $261K as of Q2 2026.
Fiduciary Trust sold 14,000 Relay Therapeutics shares in Q2 2026, an estimated $203K.
Relay Therapeutics made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #787 holding.
Fiduciary Trust first reported a position in Relay Therapeutics in Q1 2021 and has held it in 22 quarters since.
Fiduciary Trust's Relay Therapeutics position peaked at $1.02M in Q2 2021.
258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.